Motley Fool

Why Cassava Sciences Is Plunging Again Today

Shares of Cassava Sciences (NASDAQ: SAVA) are falling off a cliff yet again today, down 25% to $53 apiece as of 10:30 a.m. EDT. The company is investigating its lead drug candidate, simufilam, for treating Alzheimer’s disease. On Aug. 27, Quanterix (NASDAQ: QTRX), a third-party lab involved in the sample testing of simufilam’s disputed phase 2 results, released a statement saying that it “did not interpret the test results or prepare the data charts” regarding a key presentation on simufilam during the Alzheimer’s Association International Conference (AAIC) last month.


Please enter your comment!
Please enter your name here